CG Oncology, Inc. (NASDAQ:CGON – Get Free Report) Director Leonard Post sold 1,000 shares of CG Oncology stock in a transaction dated Monday, November 16th. The shares were sold at an average price of $92.00, for a total transaction of $92,000.00. Following the sale, the director owned 1,000 shares in the company, valued at approximately $92,000. This trade represents a 50.00% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink.
CG Oncology Stock Down 6.9%
CGON traded down $5.84 during midday trading on Tuesday, reaching $78.94. 3,160,872 shares of the company’s stock were exchanged, compared to its average volume of 1,153,223. The business has a 50-day simple moving average of $68.24 and a two-hundred day simple moving average of $66.70. The firm has a market capitalization of $7.05 billion, a price-to-earnings ratio of -28.60 and a beta of 0.35. CG Oncology, Inc. has a one year low of $37.01 and a one year high of $93.95.
CG Oncology (NASDAQ:CGON – Get Free Report) last released its quarterly earnings data on Friday, November 6th. The company reported ($0.64) earnings per share for the quarter, beating the consensus estimate of ($0.83) by $0.19. CG Oncology had a negative return on equity of 24.58% and a negative net margin of 3,851.09%. The company had revenue of $1.60 million for the quarter, compared to analyst estimates of $0.55 million. As a group, research analysts anticipate that CG Oncology, Inc. will post -3.00 EPS for the current fiscal year.
Institutional Investors Weigh In On CG Oncology
A number of hedge funds and other institutional investors have recently bought and sold shares of the business. BlackRock Inc. bought a new position in CG Oncology in the 2nd quarter valued at $444,509,000. Seven Fleet Capital Management LP grew its holdings in shares of CG Oncology by 24.5% during the second quarter. Seven Fleet Capital Management LP now owns 1,886,236 shares of the company’s stock worth $134,017,000 after purchasing an additional 371,085 shares during the last quarter. Bank of America Corp DE grew its holdings in shares of CG Oncology by 21.8% during the first quarter. Bank of America Corp DE now owns 1,449,364 shares of the company’s stock worth $98,093,000 after purchasing an additional 259,311 shares during the last quarter. Goldman Sachs Group Inc. grew its holdings in shares of CG Oncology by 32.5% during the third quarter. Goldman Sachs Group Inc. now owns 1,136,464 shares of the company’s stock worth $80,564,000 after purchasing an additional 278,751 shares during the last quarter. Finally, EcoR1 Capital LLC increased its stake in shares of CG Oncology by 3.5% in the first quarter. EcoR1 Capital LLC now owns 1,102,000 shares of the company’s stock valued at $74,583,000 after buying an additional 37,200 shares in the last quarter. 26.56% of the stock is owned by institutional investors and hedge funds.
Analyst Upgrades and Downgrades
A number of research analysts have issued reports on CGON shares. Truist Financial reissued a “buy” rating and set a $100.00 price objective (up from $85.00) on shares of CG Oncology in a report on Tuesday. Royal Bank Of Canada lowered shares of CG Oncology from an “outperform” rating to a “sector perform” rating and upped their target price for the stock from $80.00 to $97.00 in a report on Tuesday. Weiss Ratings reiterated a “sell (d-)” rating on shares of CG Oncology in a research report on Thursday, October 15th. Wedbush lifted their price target on shares of CG Oncology from $84.00 to $91.00 and gave the company an “outperform” rating in a report on Tuesday. Finally, Piper Sandler boosted their price target on shares of CG Oncology from $82.00 to $85.00 and gave the company an “overweight” rating in a research report on Friday, August 7th. Eight investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $96.11.
View Our Latest Analysis on CG Oncology
Key CG Oncology News
Investors following CGON have been watching these news items:
- Positive Sentiment: Cretostimogene cut bladder-cancer recurrence risk by 68% in the Phase 3 PIVOT-006 trial (hazard ratio 0.32; p<0.0001), meeting its primary endpoint. The company reported no Grade 3 or higher treatment-related adverse events or treatment-related discontinuations. The results could expand the drug’s reach to an estimated 50,000-patient group for which no FDA-approved adjuvant treatment is available. Reuters article
- Positive Sentiment: Analysts raised targets following the results: HC Wainwright lifted its target to $115 and kept a Buy rating; Truist raised its target to $100 and reaffirmed Buy; Wedbush increased its target to $91 and maintained Outperform. Wedbush price-target report
- Negative Sentiment: The PIVOT-006 results are topline and preliminary; approval, the breadth of any FDA label, and the planned filing timelines remain uncertain. The therapy is investigational and has not been approved by the FDA.
CG Oncology Company Profile
CG Oncology is a clinical-stage biotechnology company focused on developing treatments for bladder cancer. Based in Irvine, California, the company’s research centers on therapies delivered directly into the bladder. Its lead investigational therapy, cretostimogene grenadenorepvec (formerly CG0070), is an oncolytic immunotherapy being developed for non-muscle-invasive bladder cancer, including disease that has not responded to Bacillus Calmette-Guérin (BCG) treatment. The modified virus is designed to target cancer cells and stimulate an immune response.
Read More
- Five stocks we like better than CG Oncology
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
Receive News & Ratings for CG Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CG Oncology and related companies with MarketBeat.com's FREE daily email newsletter.
